Cargando…
The use of selexipag, a prostacyclin receptor analog, for treatment of severe pulmonary artery hypertension during pregnancy, a case report
Pregnancy in patients with pulmonary artery hypertension (PAH) is associated with high mortality and morbidity. Despite the risks, more patients with PAH are becoming pregnant. Case reports and case series have described the use of IV epoprostenol in these patients with some success. However, there...
Autores principales: | Khan, Akram, Hubel, Kinsley, Brookfield, Kathleen, Pak, Jonathan, Allada, Gopal, Gause, Sherie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374956/ https://www.ncbi.nlm.nih.gov/pubmed/37521130 http://dx.doi.org/10.1016/j.rmcr.2023.101895 |
Ejemplares similares
-
Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2022) -
Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
por: Colglazier, Elizabeth, et al.
Publicado: (2022) -
Transition from parental prostacyclin to selexipag: a case series of
five pulmonary arterial hypertension patients
por: Holthaus, Nathan, et al.
Publicado: (2019) -
First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension
por: Geerdink, Lianne M., et al.
Publicado: (2017) -
Selexipag for pulmonary arterial hypertension
Publicado: (2021)